AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.